Recent Posts
- Eyenovia To Feature Its Suite Of Commercial Products And The Optejet® Dispenser At Upcoming National Eyecare Meetings April 4, 2024
- NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals March 13, 2024
- Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th March 11, 2024
Pipeline and Technology
Corporate Address
Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017
admin@eyenovia.com
Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference
NewsEyenovia Acquires U.S. Commercial Rights To APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) From Formosa Pharmaceuticals
NewsEyenovia Announces First Commercial Sale of MydCombi™
NewsEyenovia Announces Addition to Russell 2000® and Russell 3000® Indexes
NewsEyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company’s Proprietary Optejet® Device Platform
NewsEyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update
NewsEyenovia Announces Independent Director Stephen Benjamin To Step Down To Assume Role Of Head Of White House’s Office Of Public Engagement
NewsEyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals
NewsEyenovia Reveals Positive Evidence that Optejet® Delivery Technology Decreased Inflammation from Preserved Glaucoma Solutions Compared to Drops
NewsEyenovia Announces FDA Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation
News